Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | STAT5B | P51692 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5328279 | 0.90 | ALDH1A1 (0.54) | ALDH1A1HPGDHSD11B1MAPK1TRPV1 | |
| SCHEMBL5331220 | 0.89 | HSD11B1 (0.53) | ALDH1A1HPGDHSD11B1SMN1; SMN2HSD17B10 | |
| SCHEMBL8947240 | 0.82 | ALDH1A1 (0.54) | ALDH1A1HPGDHSD11B1MAPK1KDM4E | |
| SCHEMBL8947317 | 0.78 | ALDH1A1 (0.57) | ALDH1A1HPGDHSD11B1MAPK1STAT5B | |
| SCHEMBL5966727 | 0.78 | ALDH1A1 (0.75) | ALDH1A1HPGDHSD11B1STAT5BKDM4E | |
| SCHEMBL8947278 | 0.77 | ALDH1A1 (0.70) | ALDH1A1HPGDHSD11B1MAPK1STAT5B | |
| SCHEMBL11778327 | 0.75 | ALDH1A1 (0.51) | ALDH1A1HPGDHSD11B1MAPK1KDM4E | |
| SCHEMBL5966748 | 0.75 | CYP1A2 (0.51) | ALDH1A1HPGDHSD11B1MAPK1KDM4E | |
| SCHEMBL11983631 | 0.72 | ALDH1A1 (0.76) | ALDH1A1HPGDHSD11B1STAT5BHSD17B10 | |
| SCHEMBL8947140 | 0.72 | HSD11B1 (0.59) | ALDH1A1HPGDHSD11B1SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | ALDH1A1 2972/4885HPGD 1825/4885HSD11B1 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.